D
DFTX
Definium Therapeutics
38.06
-0.15-0.39%After Hours: 37.75 -0.31 -0.81%19:56 09/30 EDT
OPEN/PREV CLOSE35.34/35.62
TODAY RANGE34.92-36.39
VOL1.97M
MARKET CAP4.71B
52 WEEK RANGE10.46-49.70
AVG VOL (3M)2.15M
% TURNOVER1.26%
TURNOVER--
P/E (TTM)-10.2372
% RANGE4.11%
EPS(TTM)-3.4277
P/E(FORWARD)-11.0889
P/B5.13
BVPS6.84
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP4.57B
SHARES OUTSTANDING134.37M
NEXT EARNINGS11/04-11/09
FREE FLOAT130.21M
LOT SIZE1
EX-DATE08/29/2022
News
Press Releases
Financial Reports
Profile
TipRanks·5d ago
Celcuity appoints Gryska to Board of Directors
Simply Wall St·09/28 23:24
Definium Therapeutics (DFTX) Stock Climbed, So What Is Behind The Fresh Attention?
Simply Wall St·09/25 09:21
Will Positive Phase 3 Anxiety Data Change Definium Therapeutics' (DFTX) Narrative
NASDAQ·09/19 23:02
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
Simply Wall St·09/19 21:30
Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?
Seeking Alpha·09/17 14:10
10 mid-cap healthcare stocks with the strongest momentum grades
TipRanks·09/17 13:55
Psychedelic: Definium’s LSD-based drug meets endpoints in GAD study
Seeking Alpha·09/17 13:45
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
TipRanks·09/16 23:08
Definium Therapeutics Logs Third Positive Phase 3 Readout for DT120 in Anxiety
TipRanks·09/16 22:38
Definium Therapeutics Issues Inducement Stock Options to New Hires
TipRanks·09/16 22:37
Definium Wins Second FDA Breakthrough Tag for Psychedelic MDD Drug
Same Industry
Name/Symbol
Change%
Price